LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | WZ-4-145 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 3377 | 5578 | 0.6054 | 0.2747 |
| SK-BR-3 | XMD16-144 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4035 | 5578 | 0.7234 | 0.4915 |
| SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4882 | 5578 | 0.8752 | 0.7707 |
| SK-BR-3 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5577 | 5578 | 0.9997 | 0.9995 |
| SK-BR-3 | BX-912 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4938 | 5578 | 0.8852 | 0.7890 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 2669 | 5578 | 0.4786 | 0.0416 |
| SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5304 | 5578 | 0.9508 | 0.9096 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5802 | 5578 | 1.0402 | 1.0738 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 1422 | 5578 | 0.2549 | -0.3695 |
| SK-BR-3 | CHIR-99021 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 4451 | 5578 | 0.7979 | 0.6286 |
| SK-BR-3 | CP724714 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 3620 | 5578 | 0.6490 | 0.3548 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6180 | 5578 | 1.1078 | 1.1981 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4361 | 5578 | 0.7818 | 0.5989 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5302 | 5578 | 0.9505 | 0.9091 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5795 | 5578 | 1.0388 | 1.0713 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5438 | 5578 | 0.9748 | 0.9537 |
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4706 | 5578 | 0.8437 | 0.7127 |
| SK-BR-3 | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6067 | 5578 | 1.0875 | 1.1609 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4825 | 5578 | 0.8650 | 0.7518 |
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5875 | 5578 | 1.0531 | 1.0976 |
| SK-BR-3 | R406 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5331 | 5578 | 0.9557 | 0.9185 |
| SK-BR-3 | Pictilisib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 3368 | 5578 | 0.6039 | 0.2719 |
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5005 | 5578 | 0.8972 | 0.8110 |
| SK-BR-3 | Geldanamycin | 0.04 | uM | LJP5 | 72 | hr | 2543 | 2298 | 5578 | 0.4119 | -0.0809 |
| SK-BR-3 | Geldanamycin | 0.04 | uM | LJP6 | 72 | hr | 2543 | 2263 | 5578 | 0.4057 | -0.0924 |